# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ada Lovelace (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI031-SYN-TD
- Date: 1851-06-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Whitley-Adeyemi, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week follow-up of abnormal bleeding and pelvic pain, with the biopsy, MRI and PET-CT results and gynecologic oncology consultation today. **S**

## History of present illness

Mrs. Lovelace returns two weeks after her first visit, on the day of her consultation with Dr. Lindgren-Osei. She stopped the opium tincture as agreed and takes oral morphine solution 5 mg with the oral syringe, about six doses a day; her average pelvic pain over the past week is 6 of 10, and she is not drowsy. The bleeding continues, lighter than before, with a watery discharge. She is a little less breathless on stairs since the iron infusion. Her bowels open every other day on senna and polyethylene glycol. She had the MRI a week ago and the PET-CT five days ago. She asked to hear all the results herself and plainly. **S**

| Element | Detail |
|---|---|
| Pain | Average 6 of 10; oral morphine 5 mg about six times a day; not drowsy |
| Bleeding | Continuing, lighter; watery discharge |
| Anemia | Less breathless since the iron infusion |
| Bowels | Every other day on laxatives |
| Preference | Wants the results told to her directly |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever; weight steady |
| Genitourinary | Positive | Lighter bleeding and watery discharge; no urinary symptoms |
| Respiratory | Negative | No cough or hemoptysis |
| Gastrointestinal | Negative | Bowels every other day; no nausea |
| Psychiatric | Positive | Anxious about the results; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain **S**
- Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole **S**
- Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 **S**
- Senna 8.6 mg tablet, two tablets by mouth at night **S**
- Polyethylene glycol 3350, 17 g in water by mouth once or twice a day **S**
- Acetaminophen 500 mg tablet, two tablets by mouth three times a day **S**
- Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/66 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 54.2 kg; BMI 19.9 kg/m². All vital signs are synthetic.

Hemoglobin: 9 g/dL (low); Creatinine: 0.66 mg/dL; ALT: 17 U/L; TSH: 1.9 mIU/L; Free T4: 1.2 ng/dL; eGFR: 117 mL/min/1.73 m²; Pelvic pain, average over the past week (0 to 10): 6. All results are synthetic.

## Change since baseline

- Hemoglobin: 8.4 g/dL (low) at baseline, 9 g/dL (low) at this visit **S**
- Creatinine: 0.68 mg/dL at baseline, 0.66 mg/dL at this visit **S**
- ALT: 18 U/L at baseline, 17 U/L at this visit **S**
- eGFR: 116 mL/min/1.73 m² at baseline, 117 mL/min/1.73 m² at this visit **S**
- Pelvic pain, average over the past week (0 to 10): 7 at baseline, 6 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Pale and alert; blood pressure 106/66, pulse 92, weight 54.2 kg |
| Lymph nodes | No supraclavicular or inguinal lymph node enlargement |
| Respiratory | Clear to auscultation |
| Abdomen | Soft; mild suprapubic tenderness; no masses or liver enlargement |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Adenocarcinoma of the cervix, FIGO 1843 stage IVB** (C53.0). The bleeding and pain now have their explanation. The cervical biopsy shows invasive adenocarcinoma of usual (HPV-associated) type, HPV 18 positive, with PD-L1 combined positive score 5, mismatch repair proficient, and HER2 1+. MRI shows a 5.2 cm tumor with left parametrial invasion; PET-CT shows avid left pelvic and para-aortic lymph nodes and six nodules in both lungs. This is stage IVB by imaging. HIV, hepatitis B and hepatitis C tests before treatment are negative. Dr. Lindgren-Osei and I told her the diagnosis together, as she asked: the cancer cannot be cured, and treatment aims to control it, stop the bleeding and relieve pain, and help her live longer and well. **S**
   - CT-guided biopsy of a lung nodule to confirm metastatic disease.
   - Palliative pelvic radiation, 20 Gy in 5 fractions, next week, for bleeding and pain.
   - Then carboplatin, paclitaxel and pembrolizumab every 3 weeks; bevacizumab not used while she is bleeding and after pelvic radiation.
   - No germline genetic testing.
   - Specialist palliative care starting today.
2. **Cancer-related pelvic pain** (G89.3). Average 6 of 10 on about 30 mg of oral morphine a day in divided doses, without sedation. Constant pain needs a long-acting opioid. **S**
   - Long-acting morphine 15 mg every 12 hours.
   - Oral morphine solution 5 mg every 4 hours as needed for breakthrough pain.
   - Continue acetaminophen 1 g three times a day and the laxatives every day.
3. **Iron deficiency anemia from blood loss** (D50.0). Hemoglobin 9.0 g/dL, from 8.4, two weeks after the first iron infusion, with bleeding continuing; no transfusion needed. **S**
   - Second ferric carboxymaltose 750 mg infusion today.
   - Ferritin 6 to 8 weeks from now.
4. **Long-term opioid therapy** (Z79.891). Using the measured morphine as directed, from this one prescriber; no signs of opioid use disorder. **S**
   - Naloxone at home; morphine in a locked box.
   - Prescription monitoring program checked: no other prescribers.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count (hemoglobin, white cells, neutrophils, platelets) | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 9.0 g/dL; full count before the first cycle |
| Laboratory | Creatinine, eGFR and ALT | Before each cycle | Completed today | Creatinine 0.66 mg/dL, eGFR 117, ALT 17 U/L |
| Laboratory | TSH and free T4 on pembrolizumab | Baseline, then every 6 weeks | Completed today | Baseline TSH 1.9 mIU/L, free T4 1.2 ng/dL before pembrolizumab |
| Laboratory | HIV, hepatitis B and hepatitis C before cancer treatment | Once, before treatment | Completed today | All negative; hepatitis B surface antibody negative, so vaccination is due |
| Laboratory | Ferritin after intravenous iron | 6 to 8 weeks after the infusions | Due | Due 6 to 8 weeks after today's second infusion |
| Examination | Vaginal bleeding and transfusion need | Every visit | Completed today | Continuing, lighter; no transfusion needed |
| Imaging | Staging: pelvic MRI and PET-CT | At diagnosis | Completed today | Stage IVB by imaging; lung biopsy to confirm |
| Survey | Pain intensity (0 to 10) and function | Every visit | Completed today | Average 6 of 10 |
| Medication safety | Opioid adverse effects: sedation, confusion, nausea | Every visit | Completed today | No sedation, confusion or nausea |
| Medication safety | Bowel regimen and constipation | Every visit | Completed today | Every other day on senna and polyethylene glycol |
| Medication safety | Naloxone, locked storage, one prescriber, prescription monitoring check | At each opioid change | Completed today | Naloxone at home; locked storage; one prescriber; monitoring check clear |
| Medication safety | Signs of opioid use disorder | Every visit | Completed today | None |
| Survey | Depression screen (PHQ-9) and distress | At diagnosis and periodically | Up to date | PHQ-9 8 at the first visit; anxious today |
| Referral | Specialist palliative care | From diagnosis of advanced cancer | Completed today | First palliative care visit today |
| Referral | Gynecologic oncology consultation | Once, at diagnosis | Completed today | Seen by Dr. Lindgren-Osei today |

## Goal progress

- Average pelvic pain at or below 3 of 10 without daytime sedation. In progress; target 1851-07-14. **S**
- Bleeding controlled and hemoglobin above 10 g/dL without transfusion. In progress; target 1851-09-08. **S**
- A documented goals-of-care conversation and a named health care agent. In progress; target 1851-09-08. **S**
- Able to work on her mathematics for at least two hours most mornings. In progress; target 1851-10-20. **S**

## Medication changes

- Started: Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026), National Comprehensive Cancer Network
- Revised FIGO staging for carcinoma of the cervix uteri (Bhatla N, et al. Int J Gynaecol Obstet 2019;145:129-135) (2018), International Federation of Gynecology and Obstetrics
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021), New England Journal of Medicine
- Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024), American Society of Clinical Oncology
- Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023), American Society of Clinical Oncology
- Patient-Clinician Communication: ASCO Guideline Update (Gilligan T, et al. J Clin Oncol 2026;44:1040-1057) (2026), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026), Aether Forge

## Follow-up

- Lung biopsy and pelvic radiation in the next ten days. Six-week review in four weeks. **S**
- Next scheduled visit 1851-07-14: six-week review: bleeding and pain after palliative pelvic radiation, the first cycle of chemotherapy with pembrolizumab, blood counts, mood and opioid safety. **S**
